Prosecution Insights
Prosecution Insights
10 pending office actions • 8 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 21 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 10 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 10 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 6 (60%) |
| No statute on record | 4 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DUFFY, BRADLEY | 1 | 54.4% | +45.4% |
| ZAIDI, SYED A | 1 | 81.8% | +12.7% |
| BELYAVSKYI, MICHAIL A | 1 | 63.8% | +27.5% |
| ANDERSON-FEARS, KEENAN NEIL | 1 | 5.9% | +50.0% |
| LOCKARD, JON MCCLELLAND | 1 | 74.5% | +27.0% |
| MELCHIOR, JAMES RYLAND | 1 | 61.0% | +44.6% |
| CORDAS, EMILY ANN | 1 | 50.6% | +58.5% |
| LIN, JERRY | 1 | 72.3% | +15.2% |
| REDDIG, PETER J | 1 | 58.0% | +40.0% |
| DHAR, MATASHA | 1 | 44.7% | +50.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19211886 | CONTENT AUTHENTICATION AND VALIDATION VIA MULTI-FACTOR DIGITAL TOKENS, SYSTEMS, AND METHODS | ZAIDI, SYED A | 23d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18225098 | COMPUTING AFFINITY FOR PROTEIN-PROTEIN INTERACTION | ANDERSON-FEARS, KEENAN NEIL | 22d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16985090 | Artificial Target Cells for in-vitro CAR Cytotoxicity and ADCC validation | DHAR, MATASHA | 743d overdue |
| 18437185 | GENERATING CIK NKT CELLS FROM CORD BLOOD | BELYAVSKYI, MICHAIL A | 175d overdue |
| 18225098 | COMPUTING AFFINITY FOR PROTEIN-PROTEIN INTERACTION | ANDERSON-FEARS, KEENAN NEIL | 22d overdue |
| 17115360 | Screening of cell clones expressing polygenic transgenes through non-antibiotic dependent positive selection | REDDIG, PETER J | 2d overdue |
| 19277274 | COMPOSITIONS AND METHODS RELATED TO POTENT CYTOTOXIC M-CENK CELLS FROM CD3/CD14-DEPLETED APHERESIS PRODUCTS | DUFFY, BRADLEY | 12d |
| 17767615 | Detecting Homologous Recombination Deficiencies (HRD) in Clinical Samples | LIN, JERRY | 16d |
| 19211886 | CONTENT AUTHENTICATION AND VALIDATION VIA MULTI-FACTOR DIGITAL TOKENS, SYSTEMS, AND METHODS | ZAIDI, SYED A | 23d |
| 18345670 | METHODS FOR STIMULATING PROLIFERATION OR DIFFERENTIATION OF AN IMMUNE CELL WITH A MULTI-CHAIN CHIMERIC POLYPEPTIDE | LOCKARD, JON MCCLELLAND | 28d |
| Art Unit | Apps |
|---|---|
| 1644 | 2 |
| 1632 | 2 |
| 1643 | 1 |
| 2432 | 1 |
| 1687 | 1 |
| 1647 | 1 |
| 1685 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19277274 | COMPOSITIONS AND METHODS RELATED TO POTENT CYTOTOXIC M-CENK CELLS FROM CD3/CD14-DEPLETED APHERESIS PRODUCTS | DUFFY, BRADLEY | 1643 | §103 | Non-Final OA | 12d | Pending | Jul 22, 2025 |
| 19211886 | CONTENT AUTHENTICATION AND VALIDATION VIA MULTI-FACTOR DIGITAL TOKENS, SYSTEMS, AND METHODS | ZAIDI, SYED A | 2432 | §103 | Non-Final OA | 23d | Pending | May 19, 2025 |
| 18437185 | GENERATING CIK NKT CELLS FROM CORD BLOOD | BELYAVSKYI, MICHAIL A | 1644 | — | Final Rejection | 175d overdue | Pending | Feb 08, 2024 |
| 18225098 | COMPUTING AFFINITY FOR PROTEIN-PROTEIN INTERACTION | ANDERSON-FEARS, KEENAN NEIL | 1687 | §103 | Non-Final OA | 22d overdue | Pending | Jul 21, 2023 |
| 18345670 | METHODS FOR STIMULATING PROLIFERATION OR DIFFERENTIATION OF AN IMMUNE CELL WITH A MULTI-CHAIN CHIMERIC POLYPEPTIDE | LOCKARD, JON MCCLELLAND | 1647 | Other | Non-Final OA | 28d | Pending | Jun 30, 2023 |
| 18258925 | Fc-Receptor CAR Constructs and Cells | MELCHIOR, JAMES RYLAND | 1644 | §103 | Non-Final OA | 54d | Pending | Jun 22, 2023 |
| 17795735 | Elimination of BCMA-positive malignancies by CAR expressing NK cells | CORDAS, EMILY ANN | 1632 | §103 | Final Rejection | 60d | Pending | Jul 27, 2022 |
| 17767615 | Detecting Homologous Recombination Deficiencies (HRD) in Clinical Samples | LIN, JERRY | 1685 | §103 | Non-Final OA | 16d | Pending | Apr 08, 2022 |
| 17115360 | Screening of cell clones expressing polygenic transgenes through non-antibiotic dependent positive selection | REDDIG, PETER J | 1646 | Other | Non-Final OA | 2d overdue | Pending | Dec 08, 2020 |
| 16985090 | Artificial Target Cells for in-vitro CAR Cytotoxicity and ADCC validation | DHAR, MATASHA | 1632 | Other | Non-Final OA | 743d overdue | Pending | Aug 04, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial